※The timeline may change depending on each project.
-
-
In need of codon optimization and UTR?
Tailored mRNA design
at your fingertips -
In need of clinical or commercial mRNA/LNP?
Brand new cGMP facility dedicated to manufacturing of mRNA/LNP
-
In need of rapid development?
Achieve success in just 3 months - the fastest route to your development journey
-
In need of simplification?
One stop solution to simplify outsourcing
-
In need of large production capacity?
Up to 100g mRNA batch
Why ARCALIS?
Your product, our passion and expertise
ARCALIS’ Minamisoma Facility
ARCALIS has built a cGMP mRNA drug substance manufacturing facility in Minamisoma City in July 2023, and completed a drug product manufacturing facility in February 2026. The world's first approved product applying a self-amplifying mRNA technology vaccine was commercialized in 2024. The Minamisoma campus includes both drug substance and drug product manufacturing facilities. In addition, ARCALIS will expand its manufacturing technology development facilities. Once completed, ARCALIS can offer one-stop manufacturing and release testing of mRNA vaccines and therapeutics.
